A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Elizabeth R. Gerstner; Xiaobu Ye; Dan G. Duda; Michael A. Levine; Tom Mikkelsen; Thomas J. Kaley; Jeffrey J. Olson; Burt L. Nabors; Manmeet S. Ahluwalia; Patrick Y. Wen; Rakesh K. Jain; Tracy T. Batchelor; Stuart Grossman

doi:10.1093/NEUONC/NOV085

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Elizabeth R. Gerstner, Xiaobu Ye, Dan G. Duda, Michael A. Levine, Tom Mikkelsen, Thomas J. Kaley, Jeffrey J. Olson, Burt L. Nabors, Manmeet S. Ahluwalia, Patrick Y. Wen, Rakesh K. Jain, Tracy T. Batchelor, Stuart Grossman

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	17
DOIs	https://doi.org/10.1093/NEUONC/NOV085
State	Published - Oct 1 2015

Disciplines

Medicine and Health Sciences
Oncology
Pathology
Internal Medicine

Access to Document

10.1093/NEUONC/NOV085License: Unspecified

Cite this

@article{770f666d04824881b36a23f1bcd68299,

title = "A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma",

author = "Gerstner, \{Elizabeth R.\} and Xiaobu Ye and Duda, \{Dan G.\} and Levine, \{Michael A.\} and Tom Mikkelsen and Kaley, \{Thomas J.\} and Olson, \{Jeffrey J.\} and Nabors, \{Burt L.\} and Ahluwalia, \{Manmeet S.\} and Wen, \{Patrick Y.\} and Jain, \{Rakesh K.\} and Batchelor, \{Tracy T.\} and Stuart Grossman",

note = "The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is the only US FDA-approved drug for recurrent glioblastoma (GBM), but the duration of response is short with most patients relapsing within 4-5 months.",

year = "2015",

month = oct,

day = "1",

doi = "10.1093/NEUONC/NOV085",

language = "American English",

volume = "17",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

AU - Gerstner, Elizabeth R.

AU - Ye, Xiaobu

AU - Duda, Dan G.

AU - Levine, Michael A.

AU - Mikkelsen, Tom

AU - Kaley, Thomas J.

AU - Olson, Jeffrey J.

AU - Nabors, Burt L.

AU - Ahluwalia, Manmeet S.

AU - Wen, Patrick Y.

AU - Jain, Rakesh K.

AU - Batchelor, Tracy T.

AU - Grossman, Stuart

N1 - The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is the only US FDA-approved drug for recurrent glioblastoma (GBM), but the duration of response is short with most patients relapsing within 4-5 months.

PY - 2015/10/1

Y1 - 2015/10/1

UR - https://academic.oup.com/neuro-oncology/article/17/10/1386/1046036

U2 - 10.1093/NEUONC/NOV085

DO - 10.1093/NEUONC/NOV085

M3 - Article

VL - 17

JO - Neuro-oncology

JF - Neuro-oncology

ER -

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Disciplines

Access to Document

Other files and links

Cite this